Results 1 to 10 of about 240,641 (402)

Correlation study of fatty pancreas and fatty liver CT manifestations with biochemical parameters in middle-aged and young adult cholecystectomy patients [PDF]

BMC Gastroenterology
Background To investigate the correlation between the occurrence of pancreatic steatosis, hepatic steatosis, and cholecystectomy, as well as the associated biochemical parameters.
Yi Zhou, Chao He, Haipeng Zhang
doaj   +2 more sources

Recovery of Bacteroides thetaiotaomicron ameliorates hepatic steatosis in experimental alcohol-related liver disease

Gut Microbes, 2022
Alcohol-related liver disease (ALD) is a major cause of liver disease and represents a global burden, as treatment options are scarce. Whereas 90% of ethanol abusers develop alcoholic fatty liver disease (AFLD), only a minority evolves to steatohepatitis
Moris Sangineto, Christoph Grander, Felix Grabherr, Lisa Mayr, Barbara Enrich, Julian Schwärzler, Marcello Dallio, Vidyasagar Naik Bukke, Archana Moola, Antonio Moschetta, Timon E. Adolph, Carlo Sabbà, Gaetano Serviddio, Herbert Tilg   +13 more
doaj   +1 more source

Multifocal nodular lesions in fatty liver mimicking neoplastic disease: a case report

Future Science OA, 2023
Usually, fatty hepatic infiltration is diffuse and homogeneous. However, in some cases, it can be localized simulating benign or malignant tumors. We present a case of a 61-year-old female patient with family history of malignancy: sister with lung ...
Manel Moalla, Amal Khsiba, Moufida Mahmoudi, Khaled Bouzaidi, Emna Chelbi, Asma Ben Mohamed, Manel Yakoubi, Mouna Medhioub, Lamine Hamzaoui, Mohamed Moussadek Azzouz   +9 more
doaj   +1 more source

Liver Ultrasound Elastography in Non-Alcoholic Fatty Liver Disease: A State-of-the-Art Summary

Diagnostics, 2023
Non-alcoholic fatty liver disease (NAFLD) is a chronic disease which is currently the most common hepatic disorder affecting up to 38% of the general population with differences according to age, country, ethnicity and sex. Both genetic and acquired risk
Rosanna Villani, Pierluigi Lupo, Moris Sangineto, Antonino Davide Romano, Gaetano Serviddio   +4 more
doaj   +1 more source

Cancer and hepatic steatosis [PDF]

ESMO Open, 2021
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent and increasing liver disease, which encompasses a variety of liver diseases of different severity. NAFLD can lead to liver cirrhosis with all its complications as well as hepatocellular carcinoma (HCC). Steatosis of the liver is not only related to obesity and other metabolic risk factors,
Paternostro, R., Sieghart, W., Trauner, M., Pinter, M.   +3 more
openaire   +2 more sources

Steatosis and Metabolic Disorders Associated with Synergistic Activation of the CAR/RXR Heterodimer by Pesticides

Cells, 2023
The nuclear receptor, constitutive androstane receptor (CAR), which forms a heterodimer with the retinoid X receptor (RXR), was initially reported as a transcription factor that regulates hepatic genes involved in detoxication and energy metabolism ...
Yannick Dauwe, Lucile Mary, Fabiana Oliviero, Marina Grimaldi, Patrick Balaguer, Véronique Gayrard, Laïla Mselli-Lakhal   +6 more
doaj   +1 more source

Indicators of carbohydrate and fat metabolism in patients with various degrees of fatty liver dystrophy

Gastroenterologìa, 2022
Background. Non-alcoholic fatty liver disease (NAFLD) ranks first among chronic liver diseases and covers almost a quarter of the population. Enough data have been accumulated on the mutual influence of metabolic changes and steatosis of the liver of ...
V.B. Yagmur, R.M. Kislova, I.A. Klenina, O.M. Tatarchuk, S.L. Melanich   +4 more
doaj   +1 more source

Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice

Molecular Therapy: Nucleic Acids, 2022
Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration of ...
Stefano Bartesaghi, Kristina Wallenius, Daniel Hovdal, Mathias Liljeblad, Simonetta Wallin, Niek Dekker, Louise Barlind, Nigel Davies, Frank Seeliger, Maria Sörhede Winzell, Sima Patel, Matt Theisen, Luis Brito, Nils Bergenhem, Shalini Andersson, Xiao-Rong Peng   +15 more
doaj   +1 more source

Western Diet Causes Obesity-Induced Nonalcoholic Fatty Liver Disease Development by Differentially Compromising the Autophagic Response

Antioxidants, 2020
Nonalcoholic fatty liver disease (NAFLD) is characterized by the development of steatosis, which can ultimately compromise liver function. Mitochondria are key players in obesity-induced metabolic disorders; however, the distinct role of hypercaloric ...
Ines C. M. Simoes, Agnieszka Karkucinska-Wieckowska, Justyna Janikiewicz, Sylwia Szymanska, Maciej Pronicki, Pawel Dobrzyn, Michal Dabrowski, Agnieszka Dobrzyn, Paulo J. Oliveira, Hans Zischka, Yaiza Potes, Mariusz R. Wieckowski   +11 more
doaj   +1 more source

Internal Ileal Diversion as Treatment for Progressive Familial Intrahepatic Cholestasis Type 1-Associated Graft Inflammation and Steatosis after Liver Transplantation

Children, 2022
Background: Progressive Familial Intrahepatic cholestasis type I (PFIC1) is a rare congenital hepatopathy causing cholestasis with progressive liver disease.
Anna M. Kavallar, Franka Messner, Stefan Scheidl, Rupert Oberhuber, Stefan Schneeberger, Denise Aldrian, Valeria Berchtold, Murat Sanal, Andreas Entenmann, Simon Straub, Anna Gasser, Andreas R. Janecke, Thomas Müller, Georg F. Vogel   +13 more
doaj   +1 more source